drug

Pravastatin

MeSH D017035
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Massachusetts General Hospital
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
NCT01082588Phase 4Completed
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
NCT00177580Phase 4Completed

KOLs & investigators

2
David J. Miklowitz, Ph.D.KOL score 5
Jaspreet S Brar, MD, MPH

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Massachusetts General Hospital
company
trial
Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia
PHASE4
trial
Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin
PHASE4
trial
indication
Schizophrenia
indication
Inflammation
indication
Schizophreniform Disorders
indication
Schizophrenia
indication
KOL
David J. Miklowitz, Ph.D.
KOL score 5
person
Jaspreet S Brar, MD, MPH
KOL score —
person